Walgreens Boots Alliance, Inc. (WBA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Add to watchlist

Visitors trend2W10W9M

38.56

+0.66

(+1.74%)

At close: 04:00PM EDT

38.59

+0.03

(+0.08%)

After hours:

07:58PM EDT

Advertisement

Full screen

Trade prices are not sourced from all markets

Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies

Chart Events

Bearishpattern detected

Momentum

View all chart patterns

Performance Outlook

Previous Close	37.90
Open	37.63
Bid	38.50 x 1100
Ask	38.60 x 3100
Day's Range	36.97 - 38.61
52 Week Range	36.97 - 55.00
Volume	9,291,855
Avg. Volume	7,142,811

Market Cap	33.326B
Beta (5Y Monthly)	0.54
PE Ratio (TTM)	6.54
EPS (TTM)	5.90
Earnings Date	Jun 30, 2022
Forward Dividend & Yield	1.91 (4.95%)
Ex-Dividend Date	May 19, 2022
1y Target Est	45.00

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.

Fair Value

XX.XX

Near Fair Value

4% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for WBA

View details

Research that delivers an independent perspective, consistent methodology and actionable insight

Related Research

Walgreens Boots Alliance, Inc.
Analyst Report: Walgreens Boots Alliance, Inc.Walgreens Boots Alliance is a leading retail pharmacy chain with about 13,000 stores in the U.S. and internationally. Walgreens’ core strategy involves brick-and-mortar retail pharmacy locations in high-traffic areas, with nearly 80% of the U.S. population living within 5 miles of a store. Currently, the company has a leading share of the domestic prescription drug market at about 20%. In 2021, the company sold a majority of its Alliance Healthcare wholesale business to AmerisourceBergen for $6.5 billion, doubling down on its core pharmacy efforts and ventures in strategic growth areas in primary care (VillageMD) and digital offerings. The company also has equity stakes in AmerisourceBergen (29%) and Sinopharm Holding Guoda Drugstore (40%).
Rating
Fair Value
Economic Moat
4 days agoMorningstar